

IFW

Atty. Docket No.: 9000/2022

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Faeldt, et al.
Serial No.: 10/618,913
Filed: July 14, 2003
Entitled: Method for Identification of
Biologically Active Agents

Examiner: Not Yet Assigned
Group Art Unit: 1638
Conf. No.: 7967

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Nancy Arsenault

Name of Person Mailing Paper

Signature of Person Mailing Paper

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent application, please find the following documents:

1. Information Disclosure Statement;
2. Form PTO-1449;
3. Copies of Cited References; and
4. Return Post Card.

The Commissioner for Patents is hereby authorized to charge any fees to Deposit Account No. 16-0085, Reference 9000/2022. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Date: 9/10/04

Name: Matthew Beaudet
Registration No.: 50,649
Customer No.: 29933
Palmer & Dodge LLP
111 Huntington Avenue
Boston, MA 02199-7613
Tel: 617-239-0100



Atty. Docket No.: 9000/2022

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Faeldt, et al.
Serial No.: 10/618,913
Filed: July 14, 2003
Entitled: Method for Identification of
Biologically Active Agents

Examiner: Not Yet Assigned
Group Art Unit: 1638
Conf. No.: 7967

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Nancy Arsenault

Name of Person Mailing Paper

Signature of Person Mailing Paper

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98**

Dear Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicant submits this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office.

A listing of the cited documents is also enclosed, as well as, for the Examiner's convenience, copies of the documents in the list.

Pursuant to CFR § 1.97(b)(3), because this Statement is being submitted before the first Office Action on the merits, no fee is required.


Applicant does not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Date: 9/10/04

Respectfully submitted,

Name: Matthew Beaudet
Registration No.: 50,649
Customer No.: 29933
Palmer & Dodge LLP
111 Huntington Avenue
Boston, MA 02199-7613
Tel: 617-239-0100



USPTO Form 100 Patent and Trademark Office U.S. Department of Commerce				Attorney Docket No. 9000/2022		Serial No. 10/618,913	
INFORMATION DISCLOSURE STATEMENT				Applicant(s): Faeldt, et al.			
				Filing Date: July 14, 2003		Group: 1638	
U.S. PATENT DOCUMENTS							
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
FOREIGN PATENT DOCUMENTS							
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation
							YES NO
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)							
	1.	Chan and Bonini; "Drosophila models of human neurodegenerative disease"; (2000); <u>Cell Death and Differentiation</u> ; 7: 1075-1080.					
	2.	Feany and Bender; "A Drosophila model of Parkinson's disease"; (2000); <u>Nature</u> ; 404: 394-398.					
	3.	Fernandez-Funez, et al.; "Identification of genes that modify ataxin-1-induced neurodegeneration"; (2000); <u>Nature</u> ; 408: 101-106.					
	4.	Fortini and Bonini; "Modeling human neurodegenerative diseases in Drosophila"; (2000); <u>Trends Genet.</u> ; 16: 161-167.					
	5.	Jackson, et al.; "Polyglutamine-Expanded Human Huntington Transgenes Induce Degeneration of Drosophila Photoreceptor Neurons"; (1998); <u>Neuron</u> ; 21: 633-642.					
	6.	Kazemi-Esfarjani and Benzer; "Genetic Suppression of Polyglutamine Toxicity in Drosophila"; (2000); <u>Science</u> ; 287: 1837-1840.					
	7.	Warrick, et al.; "Expanded Polyglutamine Protein Forms Nuclear Inclusions and Causes Neural Degeneration in Drosophila"; (1998); <u>Cell</u> ; 93: 939-949.					
	8.	Brand and Perrimon; "Targeted gene expression as a means of altering cell fates and generating dominant phenotypes"; (1993); <u>Development</u> ; 118: 401-415.					
	9.	Marsh, et al.; "Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila"; (2000); <u>Hum. Mol. Genet.</u> ; 9: 13-25.					
EXAMINER					DATE CONSIDERED		
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p> <p>**Copies of references not provided at the time of this submission.</p>							